NOVEN EARNS MILESTONE PAYMENT UNDER P&G COLLABORATION

Noven Pharmaceuticals has earned a $3 million success fee for attaining a development milestone under its development collaboration with P&G Pharmaceuticals, a subsidiary of The Procter & Gamble Company. Noven expects to report the $3 million success fee as license and contract revenues for the quarter ending Dec. 31, 2004.

PharmaBiz (http://www.pharmabiz.com/article/detnews.asp?articleid=25506)